PHENYLASE
Phenylketonuria (PKU)
BioMarin Pharmaceuticalprotein_peptidePhase 4 / ApprovedActive
A
81/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 72/ 100
- Competitive Position
- 95/ 100
Competitive context
18 Active assets in the Phenylketonuria (PKU) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sapropterin Dihydrochloride Sohag University | Phase 4 | A |
Ravpal-Peg BioMarin Pharmaceutical | Phase 2 | BB |
Repinatrabit Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | BB |
ESCHERICHIA COLI STRAIN SYNB1618 Synlogic | Phase 2 | BB |
L-Carnitine Mansoura University | Phase 4 | BB |
View all 29 →
Same molecule, other indications
PHENYLASE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →